Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

Artur Plonowski, Andrew V. Schally, Jozsef L. Varga, Z. Rékási, Francine Hebert, Gabor Halmos, Kate Groot

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

BACKGROUND. In view of the involvement of various neuropeptides and growth factors in the progression of androgen-independent prostate cancer, we investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone or in combination with an antagonist of bombesin/gastrin- releasing peptide (BN/GRP) on PC-3 human prostate cancers. METHODS. Nude mice implanted with PC-3 tumors received GHRH antagonists MZ-5-156 or JV-1-38, each at 20 μg/day s.c. In experiment 2, treatment consisted of daily injections of JV-1-38 (20 μg), BN/GRP antagonist RC-3940-II (10 μg), or a combination of JV-1-38 and RC-3940-II. Serum IGF-I levels, expression of mRNA for IGF-II, and characteristics of BN/GRP and EGF receptors in tumor tissue were investigated. RESULTS. JV-1-38 induced a greater inhibition of tumor growth and suppression of IGF-II mRNA than MZ-5-156, both compounds causing a similar decrease in serum IGF-I. In experiment 2, JV-1-38 and RC-3940-II produced a comparable reduction in tumor volume (65% and 61%, respectively), but a combination of both antagonists augmented tumor inhibition to 75%. Combined treatment with JV-1-38 and RC-3940-II also led to a greater suppression of IGF-II mRNA (92%), as compared with JV-1-38 (72%) or RC-3940- II (77%). Serum IGF-I concentration was lowered only in mice treated with JV- 1-38, while the downregulation of BN/GRP and EGF receptors was specific for groups receiving RC-3940-II. CONCLUSIONS. The inhibitory effects of GHRH antagonists on PC-3 human androgen-independent prostate cancer can be potentiated by concomitant use of BN/GRP antagonists. The combination of both types of analogs apparently interferes with both IGF and bombesin/EGF pathways, and might be clinically useful for the management of androgen- independent prostate cancer. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)172-180
Number of pages9
JournalProstate
Volume44
Issue number2
DOIs
Publication statusPublished - Jul 1 2000

Fingerprint

Hormone Antagonists
Bombesin
Growth Hormone-Releasing Hormone
Epidermal Growth Factor
Gastrin-Releasing Peptide
Prostatic Neoplasms
Insulin-Like Growth Factor II
Insulin-Like Growth Factor I
Androgens
Messenger RNA
Neoplasms
Serum
JV 1-38
Tumor Burden
Neuropeptides
Nude Mice
Hca(6)-Leu(13)-psi(CH2N)-Tac(14)-bombesin(6-14)
Intercellular Signaling Peptides and Proteins
Down-Regulation
Injections

Keywords

  • Androgen-independent prostate cancer
  • Antagonist of bombesin/gastrin-releasing peptide
  • Antagonist of growth hormone- releasing hormone
  • Epidermal growth factor
  • Insulin-like growth factor

ASJC Scopus subject areas

  • Urology

Cite this

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. / Plonowski, Artur; Schally, Andrew V.; Varga, Jozsef L.; Rékási, Z.; Hebert, Francine; Halmos, Gabor; Groot, Kate.

In: Prostate, Vol. 44, No. 2, 01.07.2000, p. 172-180.

Research output: Contribution to journalArticle

Plonowski, Artur ; Schally, Andrew V. ; Varga, Jozsef L. ; Rékási, Z. ; Hebert, Francine ; Halmos, Gabor ; Groot, Kate. / Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. In: Prostate. 2000 ; Vol. 44, No. 2. pp. 172-180.
@article{d3b5832915d64f31aa07b53768ffe7f6,
title = "Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways",
abstract = "BACKGROUND. In view of the involvement of various neuropeptides and growth factors in the progression of androgen-independent prostate cancer, we investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone or in combination with an antagonist of bombesin/gastrin- releasing peptide (BN/GRP) on PC-3 human prostate cancers. METHODS. Nude mice implanted with PC-3 tumors received GHRH antagonists MZ-5-156 or JV-1-38, each at 20 μg/day s.c. In experiment 2, treatment consisted of daily injections of JV-1-38 (20 μg), BN/GRP antagonist RC-3940-II (10 μg), or a combination of JV-1-38 and RC-3940-II. Serum IGF-I levels, expression of mRNA for IGF-II, and characteristics of BN/GRP and EGF receptors in tumor tissue were investigated. RESULTS. JV-1-38 induced a greater inhibition of tumor growth and suppression of IGF-II mRNA than MZ-5-156, both compounds causing a similar decrease in serum IGF-I. In experiment 2, JV-1-38 and RC-3940-II produced a comparable reduction in tumor volume (65{\%} and 61{\%}, respectively), but a combination of both antagonists augmented tumor inhibition to 75{\%}. Combined treatment with JV-1-38 and RC-3940-II also led to a greater suppression of IGF-II mRNA (92{\%}), as compared with JV-1-38 (72{\%}) or RC-3940- II (77{\%}). Serum IGF-I concentration was lowered only in mice treated with JV- 1-38, while the downregulation of BN/GRP and EGF receptors was specific for groups receiving RC-3940-II. CONCLUSIONS. The inhibitory effects of GHRH antagonists on PC-3 human androgen-independent prostate cancer can be potentiated by concomitant use of BN/GRP antagonists. The combination of both types of analogs apparently interferes with both IGF and bombesin/EGF pathways, and might be clinically useful for the management of androgen- independent prostate cancer. (C) 2000 Wiley-Liss, Inc.",
keywords = "Androgen-independent prostate cancer, Antagonist of bombesin/gastrin-releasing peptide, Antagonist of growth hormone- releasing hormone, Epidermal growth factor, Insulin-like growth factor",
author = "Artur Plonowski and Schally, {Andrew V.} and Varga, {Jozsef L.} and Z. R{\'e}k{\'a}si and Francine Hebert and Gabor Halmos and Kate Groot",
year = "2000",
month = "7",
day = "1",
doi = "10.1002/1097-0045(20000701)44:2<172::AID-PROS10>3.0.CO;2-Z",
language = "English",
volume = "44",
pages = "172--180",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

AU - Plonowski, Artur

AU - Schally, Andrew V.

AU - Varga, Jozsef L.

AU - Rékási, Z.

AU - Hebert, Francine

AU - Halmos, Gabor

AU - Groot, Kate

PY - 2000/7/1

Y1 - 2000/7/1

N2 - BACKGROUND. In view of the involvement of various neuropeptides and growth factors in the progression of androgen-independent prostate cancer, we investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone or in combination with an antagonist of bombesin/gastrin- releasing peptide (BN/GRP) on PC-3 human prostate cancers. METHODS. Nude mice implanted with PC-3 tumors received GHRH antagonists MZ-5-156 or JV-1-38, each at 20 μg/day s.c. In experiment 2, treatment consisted of daily injections of JV-1-38 (20 μg), BN/GRP antagonist RC-3940-II (10 μg), or a combination of JV-1-38 and RC-3940-II. Serum IGF-I levels, expression of mRNA for IGF-II, and characteristics of BN/GRP and EGF receptors in tumor tissue were investigated. RESULTS. JV-1-38 induced a greater inhibition of tumor growth and suppression of IGF-II mRNA than MZ-5-156, both compounds causing a similar decrease in serum IGF-I. In experiment 2, JV-1-38 and RC-3940-II produced a comparable reduction in tumor volume (65% and 61%, respectively), but a combination of both antagonists augmented tumor inhibition to 75%. Combined treatment with JV-1-38 and RC-3940-II also led to a greater suppression of IGF-II mRNA (92%), as compared with JV-1-38 (72%) or RC-3940- II (77%). Serum IGF-I concentration was lowered only in mice treated with JV- 1-38, while the downregulation of BN/GRP and EGF receptors was specific for groups receiving RC-3940-II. CONCLUSIONS. The inhibitory effects of GHRH antagonists on PC-3 human androgen-independent prostate cancer can be potentiated by concomitant use of BN/GRP antagonists. The combination of both types of analogs apparently interferes with both IGF and bombesin/EGF pathways, and might be clinically useful for the management of androgen- independent prostate cancer. (C) 2000 Wiley-Liss, Inc.

AB - BACKGROUND. In view of the involvement of various neuropeptides and growth factors in the progression of androgen-independent prostate cancer, we investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone or in combination with an antagonist of bombesin/gastrin- releasing peptide (BN/GRP) on PC-3 human prostate cancers. METHODS. Nude mice implanted with PC-3 tumors received GHRH antagonists MZ-5-156 or JV-1-38, each at 20 μg/day s.c. In experiment 2, treatment consisted of daily injections of JV-1-38 (20 μg), BN/GRP antagonist RC-3940-II (10 μg), or a combination of JV-1-38 and RC-3940-II. Serum IGF-I levels, expression of mRNA for IGF-II, and characteristics of BN/GRP and EGF receptors in tumor tissue were investigated. RESULTS. JV-1-38 induced a greater inhibition of tumor growth and suppression of IGF-II mRNA than MZ-5-156, both compounds causing a similar decrease in serum IGF-I. In experiment 2, JV-1-38 and RC-3940-II produced a comparable reduction in tumor volume (65% and 61%, respectively), but a combination of both antagonists augmented tumor inhibition to 75%. Combined treatment with JV-1-38 and RC-3940-II also led to a greater suppression of IGF-II mRNA (92%), as compared with JV-1-38 (72%) or RC-3940- II (77%). Serum IGF-I concentration was lowered only in mice treated with JV- 1-38, while the downregulation of BN/GRP and EGF receptors was specific for groups receiving RC-3940-II. CONCLUSIONS. The inhibitory effects of GHRH antagonists on PC-3 human androgen-independent prostate cancer can be potentiated by concomitant use of BN/GRP antagonists. The combination of both types of analogs apparently interferes with both IGF and bombesin/EGF pathways, and might be clinically useful for the management of androgen- independent prostate cancer. (C) 2000 Wiley-Liss, Inc.

KW - Androgen-independent prostate cancer

KW - Antagonist of bombesin/gastrin-releasing peptide

KW - Antagonist of growth hormone- releasing hormone

KW - Epidermal growth factor

KW - Insulin-like growth factor

UR - http://www.scopus.com/inward/record.url?scp=0034234650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034234650&partnerID=8YFLogxK

U2 - 10.1002/1097-0045(20000701)44:2<172::AID-PROS10>3.0.CO;2-Z

DO - 10.1002/1097-0045(20000701)44:2<172::AID-PROS10>3.0.CO;2-Z

M3 - Article

C2 - 10881027

AN - SCOPUS:0034234650

VL - 44

SP - 172

EP - 180

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 2

ER -